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II Microsatellite instability has a positive prognostic impact on stage II colorectal 









III Mutations in BRAF and KRAS identify stage-specific subgroups of colon cancer 
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A century of research on the genetics of colorectal cancer - 
The History of Lynch Syndrome. 
 
“The statistical study of carcinoma is regarded by many writers 
as having been carried as far as it can be profitable” 
A. S. Warthin, 1913 
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Amsterdam criteria (1990) 
At least 3 relatives with histologically confirmed colorectal cancer, 1 of whom is a first 
degree relative of the other 2; familial adenomatous polyposis should be excluded.  
At least 2 successive generations involved. 
At least 1 of the cancers diagnosed before age 50. 
All criteria must be fulfilled to be included in further analyses. 
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The Bethesda Guidelines for testing tumors for microsatellite instability (1996) 
1. Individuals with cancer in families that meet the Amsterdam Criteria. 
2. Individuals with two HNPCC-related cancers, including synchronous and metachronous 
colorectal cancers or associated extracolonic cancers (endometrial, ovarian, gastric, 
hepatobiliary, small bowel, or transitional cell carcinoma of the renal pelvis or ureter). 
3. Individuals with colorectal cancer and a first-degree relative with colorectal cancer 
and/or HNPCC-related extracolonic cancer and/or a colorectal adenoma; one of the 
cancers diagnosed at age <45 y, and the adenoma diagnosed at age <40 y. 
4. Individuals with colorectal cancer or endometrial cancer diagnosed at age <45 y. 
5. Individuals with right-sided colorectal cancer with an undifferentiated pattern on 
histopathology diagnosed at age <45 y. 
6. Individuals with signet-ring-cell-type (> 50%) in colorectal cancer diagnosed at age 
<45. 
7. Individuals with adenomas diagnosed at age <40 y. 
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Amsterdam criteria II (1998) 
3 or more relatives with an associated cancer (colorectal cancer, or cancer of the 
endometrium, small intestine, ureter or renal pelvis). 1 should be a first-degree relative of 
the other two. Tumors should be verified by pathologic examination. Familial 
adenomatous polyposis (FAP) should be excluded in cases of colorectal carcinoma. 
2 or more successive generations affected. 
1 or more relatives diagnosed before the age of 50 years. 




The Revised Bethesda Guidelines (2002) 
1. Colorectal carcinoma (CRC) diagnosed in a patient who is less than 50 years old. 
2. Presence of synchronous or metachronous CRC or other Lynch syndrome-associated 
tumors, regardless of age. 
3. CRC with high microsatellite instability histology diagnosed in a patient less than 60 
years old. 
4. CRC diagnosed in one or more first-degree relatives with a Lynch syndrome-associated 
tumor, with one of the cancers being diagnosed at less than 50 years of age. 
5. CRC diagnosed in two or more first-degree or second-degree relatives with Lynch 
syndrome-associated tumors, regardless of age. 
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Epigenetics has been defined amongst others by Andrew Feinberg:  
 
“Cellular information, other than the sequence itself,  
that is heritable during cell division” [50].  
 
There are several types of epigenetic changes observed in cancer; global hypomethylation, 
hypermethylation of specific CpG sites, loss of imprinting, and histone modifications. These 
changes modify expression of genes, and by silencing of tumor suppressors or activation of 
oncogenes they can contribute to carcinogenesis. Both genetic and epigenetic changes in cancer 
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Colorectal cancer  
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Figure 2. Trends in incidence and mortality rates and 5-year relative survival proportions. From 










ǡ     ǡ     ʹǦͷΨ  





 Ǥ            
Ǥ
          
  ͷ  ȏ͸ͶȐǤ        ǡ   
ǦǤ

Tests for occult blood.   ȋ	Ȍǡ
      Ǥ 	      
Ǥ              
 ͵ͷΨ  ͺͲΨ  ͵ͲΨ  ͹ͲΨǡ  ȏ͸ͷȐ     





Fecal DNA.       ǡ    
Ǥͳͻͻ͵ǡ
       ͺȀͻ   
 ȏ͸ͺȐǤ 	       ȋǡ ͷ͵ǡ
Ǧʹ͸ǡȌʹͳǤ
ȏ͸ͻȐǡͷʹΨ
 ͳͺΨ           
       Ǥ    ͻͶΨ ȏ͹ͲȐǤ 






Table 5. Hereditary colorectal cancer syndromes with affected genes and clinical features. 





PMS2 or MSH6 
(EPCAM) 
No polyposis. 80% lifetime risk of colorectal cancer, 
mean age 44 years. Similar risk for cancer in the 
endometrium and ovaries. Increased risk of cancer in 
the stomach, urinary tract, small bowel and central 
nervous system. 
FAP 




Develop adenomatous polyps (> 100) in colon and 
rectum after adolescence. Carcinoma diagnosis by 
mean age of 35-40 years. Also polyps/carcinoma in 
the duodenum, the stomach and hypertrophy of 
retinal pigment epithelium. 
Gardner’s syndrome APC 
Phenotypic variant of FAP: Same features in addition 
to epidermoid cysts, desmoid tumors and osteomas. 
AFAP 




Less pronounced phenotype of FAP with as few as 10-
20 adenomatous polyps by 50 years of age. 
Carcinoma by mean age of 55 years. 
Turcot’s syndrome 
APC, MLH1 or 
MSH2 
Multiple adenomatous colon polyps and increased 
risk of colorectal cancer. Increased risk of 
medulloblastomas (associated with APC mutation) 






Variant of AFAP. Autosomal recessive inheritance 
pattern. Usually no family history. Few colorectal 




Hamartomatous polyps in the GI tract and 
mucocutaneus lesions of hyperpigmentation in the 
mouth and on the hands and feet. Increased risk of 
carcinomas in the pancreas, liver, lungs, breast, 
ovaries, uterus and testis. Cumulative risk by age of 
70 for all cancers is 85%. 
Cowden disease PTEN 
Small benign hamartomas in skin and mucous 
membranes as the mouth and GI tract. Increased risk 
of cancer in breast, thyroid, uterus and kidney. 





Multiple polyps, sessile or pedunculated 
hamartomatous, primarily in colon and stomach. 60% 
risk of colorectal cancer by 60 years. Increased risk of 
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Computed tomographic colonography/ Virtual colonoscopy.   
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Symptoms and signs in colorectal cancer. 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Diagnostic and preoperative examinations. 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Table 6. The TNM classification. 
 TNM Clinical Classification 
T-stage Primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria. 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 
Tumor invades through muscularis propria into pericolic or perirectal 
tissue. 
T4 
Tumor invades other organs or structures and/or perforates visceral 
peritoneum 
T4a (7
th ed.) Tumor penetrates visceral peritoneum 
T4b (7
th ed.) Tumor invades or is adherent to other organs or structures 
N-stage Metastatic regional lymph nodes 
N0 No regional lymph node metastasis 
N1 Metastasis to 1-3 regional lymph nodes 
N2 Metastasis to ш4 regional lymph nodes 
N1a (7
th ed.) Metastasis to 1 regional lymph nodes 
N1b (7
th ed.) Metastasis to 2-3 regional lymph nodes 
N1c (7
th ed.) Tumor deposit in the pericolic/perirectal tissue  
N2a (7
th ed.) Metastasis to 4-6 regional lymph nodes 
N2b (7
th ed.) Metastasis to ш7 regional lymph nodes 
M-stage Distant metastasis 
M0 No distant metastases 
M1 Distant metastases 
M1a (7
th ed.) Metastasizing to only one organ or one site 
M1b (7
th ed.) Metastasizing to multiple organs or peritoneal dissemination 
 Histopathological grading 
G-stage Grade of differentiation 
GX Grade of differentiation cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated 
 R-Classification 
R-stage Residual tumor 
R0 No residual tumor 
R1 Microscopic residual tumor (cancer cells ч1mm from the res. margin) 







Table 7. Outline of the different editions of “TNM Classification of Malignant Tumors” 
 Edition 
TNM-stage 5th (1997) 6th (2002) 7th (2009) 
I T1-2, N0, M0 T1-2, N0, M0 T1-2, N0, M0 
II T3-4, N0, M0   
IIA  T3, N0, M0 T3, N0, M0 
IIB  T4, N0, M0 T4a, N0, M0 
IIC   T4b, N0, M0 
III T1-4, N1-2, M0   
IIIA  T1-2, N1, M0 T1-2, N1, M0 / T1, N2a, M0 
IIIB  T3-4, N1, M0 
T3-4a, N1, M0 / T2-3, N2a, M0  / 
T1-2, N2b, M0 
IIIC  T1-4, N2, M0 
T4a, N2a, M0 / T3-4a, N2b, M0 / 
T4b, N1-2, M0 
IV T1-4, N1-2, M1 T1-4, N1-2, M1  
IVA   T1-4, N1-2, M1a 
IVB   T1-4, N1-2, M1b 
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Morphologic and molecular development of colorectal cancer. 
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Figure 3. Endoscopic and Histological Features of Aberrant Crypt Foci. Panel A: Endoscopy with 
methylene blue staining reveals a small focus consisting of four crypts with semicircular or oval 
lumens. Panel B: Histologically, there was slight enlargement, irregularity, and elongation of the 
ducts, findings consistent with features of aberrant crypt foci without dysplasia or hyperplasia. 
Panel C: A medium focus consisting of 13 crypts, each with an asteroid or slit shape. Panel D: 
Histologically, there was a serrated luminal pattern, characteristic of aberrant crypt foci with 
hyperplasia. Panel E: A large focus with a deformed and slightly raised shape. The epithelial lining 
was thicker than those of the foci shown in Panels A and C, and each lumen was compressed or 
not distinct. Panel F: Histological examination revealed a loss of polarity, hyperchromatism of the 
nuclei, and stratification of the nuclei of crypt epithelium, findings in agreement with the 
previously reported features of dysplastic aberrant crypt foci. Endoscopy with methylene blue 
and histology with hematoxylin and eosin staining (x180 in B, x150 in D, and x120 in F).  
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Figure 4. Serrated polyps with abnormal proliferation. Panel A: Irregularly distributed short 
segments of epithelium with lack of maturation (absence of mucin production), pseudo-
stratification and an increased nucleus to cytoplasmic ratio (circled areas), are morphologic 
evidence of abnormal proliferation. Such segments are typically, seen luminal to segments of 
epithelium with normal proliferation. Panel B: The right dilated crypt has a proliferative 
appearance in the base, whereas the left dilated crypt does not. Asymmetry may also be 
observed in a single crypt. Panel C: Elongation, crowding, and stratification of the nuclei are 
present on the left side (dotted line arrow), whereas hypermature epithelium with goblet cells is 
seen only on the right side. In addition, proliferative epithelium is displaced toward the lumen 
(full line arrow). Panel D: The presence of mitoses close to the surface also indicates proliferation.  
Hematoxylin and eosin staining (×100 in A–C, ×400 in D). Reproduced with permission from [114], 
Copyright Lippincott Williams & Wilkins, Inc. Text slightly modified. 
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Sessile serrated adenoma/polyp Traditional 
serrated 
adenoma No dysplasia With dysplasia 
Molecular Frequency 
CIMP-H +1 +++ +++ ++ 
MLH1-methylation - - ++ - 
MSI - - ++ - 
BRAF mutation +1 +++ +++ + 
KRAS mutation +2 - - + 
Clinical Frequency 
Prevalence (%) Very common Common Rare 
Proportion of 
serrated lesions 













Larger than HP Larger than HP 
Precancerous no yes yes 
Surveillance Suggestions 
Interval in years3 5-10 1-5 1-3 3-5 
1MVHP commonly have CIMP-H and BRAF mutation 
2GCHP commonly have KRAS mutation 
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Molecular phenotypes in sporadic colorectal cancer 
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CpG methylator phenotype (CIMP)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The CpG dinucleotide and the definition of a CpG Island 
 
A cytosine (C) followed by a guanine (G) at the same DNA strand, represents the most frequently 
methylated nucleotide in the genome. The CG dinucleotide is called CpG where “p” refers to the 
phosfodiester bound between the nucleotides.  
 
A CpG Island are defined as a DNA region of at least 500bp where the C+G frequency is higher 
than 55% and the observed to expected CpG ratio is more than 65% [141]. About 40% of all 
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Figure 7. Venn diagram showing the relationships between the different molecular subtypes in 
colorectal cancer. CIN is here defined as aberration in chromosome 2p, 3p, 5q, 17p, and/or 18q 
[148]. Analyses were performed in a cohort of 60 patients and the numbers correspond to 










Prognosis (Greek. pro-gnosis, foreknowledge) -  
a forecast as to the probable course and outcome of a disease 
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Micrometastases and isolated tumor cells in lymph nodes. 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Lymphoid reaction    ǢǯǦ
 ǡ   ǡ   ǡ
ǦǤǡǡ
ǡǡȏͳͺͻȐǤ






        ǡ     
ǦȏͳͻͳǦͳͻ͵ȐǤ





           ͳͻͷͲ ȏͳͻͷȐǤ  
         
ȋȌǡȏͳͻ͸ȐǤ
      ǡ  ǡ   
ȏͳͻ͹ȐǤ















 ǡ   ǡ        
    ȏʹͲ͵ȐǤ            





ͳͶͻ            

 ͹ͲΨ   ǡ      ͷ ȏʹͲ͸ȐǤ    




Microsatellite instability (MSI)        




KRAS   Ǧ      Ǥ      ǲ







     ͵ͲǦͶͲΨ    Ǧ  




             
 ȋ
	Ȍ ȏʹͳͷȐǤ 	ȏʹͳ͸Ȑ 






           
ȏʹͳͺȐǤ

    KRAS   Ǥ  ǲ ǳ ǡ  
          ͳʹ  
  ȏʹͳͻȐǤ       ȏʹʹͲȐǡ 
Ǥ

   ǡ   KRAS     
     Ǧ
	  ȏʹʹͳȐǤ Ǧ





 	ȏʹʹ͵ȐǤ   Ǧ
ȋȌǡǦǦ
ȋȌ  ǡ    ǡ Ǧ ǡ 
ȋ	ͺȌȏʹʹͶǡʹʹͷȐǤ

    ͳͲǦͳͷΨ   ȏʹͳͶǡ ʹʹ͸Ȑǡ ͸ͲͲ 
ȏʹʹ͹ȐǤ
Ǥ       
       ǡ     
KRASȏʹʹ͵ȐǤ

 BRAF           ǡ
















 ǡ  ȏʹ͵ͻȐǤ͵  ͵ 









    PIK3CA     Ǧ
	   
ȏʹͶͶǦʹͶ͸ȐǤ

PTEN.      ȋȌ     Ǥ 
͵ǡ͵ȋ	
ͺȌǤ     Ǥ
















 ǡ        ȋȌ ȏʹͷ͵ȐǤ   
       ȏʹͷͶǡ ʹͷͷȐ      
    ͳͻͺʹ ȏʹͷ͸ȐǤ  














Gene expression signatures 

















 ʹͲͳʹ          

















          ǡ  
Ǥ











The clinical database and tissue
ͳͻͻ͵ǡ  
            Ǥ 

ǡȋȌǡ
     Ǥ       
      
 ǡ     ǡ   ǡ   ǡ






   Ǥ	
  ǡ         
ǡ          Ǥ  
Ǧǡǡ
 ǡ       Ǥ      
      ǡ      





    Ǥ 	        
Ǥ             
  
         
   ¤    ʹͲͳʹ     
    Ǥ  ʹͲ ǡ     ʹͷͲͲ
MATERIAL AND METHODS 
ͷͺ

              
Ǥ

 ʹͲͲͷǡ         ͳͻͻ͵  ʹͲͲ͵ 
Ǥ
      ǡ       
Ǥ
   Ǧ           



















   Ǥ   
Ǧ
Ǥ
   
Ǥͳͷ
Ǥ      
           ǡ  
 Ǥ         ǡ
Ǥ












 ȏ͵ʹȐǤ  
Ǥ
     
Ǥ

Staging and tumor grade ͷǤ
  ʹ  ͵ǡ  ȋ
ͳȌ   ȋ
ʹȌ    
   Ǥ   ͵ǡ  ȋ
͵Ȍ   
Ǥ

R-status     Ǥ  ǣ       
ʹ  ǡ
         Ǥ  
             
ǡͲǤ











  Ǥ          
  ǡ      
Ǥ
MATERIAL AND METHODS 
͸Ͳ

Urgency of surgery. Ǥ
           Ǥ
ǡǡ




Examination of lymph nodes.







	   ǡ         
     KRASǡ BRAFǡ PIK3CA  PTENǤ    
 Ǧ ʹͲͳʹǤ    ȋ  ȏȐȌ 
ȋǡ 	ǡ ͵   ȏ  ȐȌ  ȋ   
  ȏ  ȐȌ    ͳͲͻͲ  
   ǡ ǡ  Ǥ      ǡ 
Ǥ
      ǡ     ǡ 
















Figure 9. Summary of literature review and selection of papers in literature table. 
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Analyses of microsatellite instability (MSI) 
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Mutation analyses in KRAS, BRAF, PIK3CA, and PTEN. 
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Figure 10. Fragment analyses of BAT 25 and BAT 26. Panels showing fragment analyses of BAT 25 
and BAT 26. The first panel for each marker show normal fragment length (MSS), while the lower 
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Figure 11. V600E mutations in the BRAF gene. Three panels showing the sequences of codon 596 
to 604 in BRAF. The first panel shows a normal sequence while the second and third panel 
demonstrate a mutation in codon 600. T (Thymine) is replaced by a A (Adenine) at position 1799 
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RESULTS IN BRIEF 
 
Paper I:  
 
Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in 
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Microsatellite instability has a positive prognostic impact on stage II 
colorectal cancer after complete resection: results from a large, 
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BRAF-mutation has negative prognostic impact in microsatellite 
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Quality of the clinical and histopathological data 
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Formalin fixed paraffin embedded tissue - pro and cons 
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Marker panel for MSI determination 
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Mutation hot spots 
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Relevance of the study 
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Our findings and their clinical impact 
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The Will Rogers phenomenon is obtained when moving an element  
from one set to another, raises the average values of both sets. 
 
It is based on the following quote, attributed to American comedian 
William Penn Adair "Will" Rogers (1879–1935): 
 
“When the Okies left Oklahoma and moved to California, 
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Background: Microsatellite instability (MSI) was suggested as a marker for good prognosis in colorectal cancer in
1993 and a systematic review from 2005 and a meta-analysis from 2010 support the initial observation. We here
assess the prognostic impact and prevalence of MSI in different stages in a consecutive, population-based series from
a single hospital in Oslo, Norway.
Patients and methods: Of 1274 patients, 952 underwent major resection of which 805 were included in analyses of
MSI prevalence and 613 with complete resection in analyses of outcome. Formalin-ﬁxed tumor tissue was used for
PCR-based MSI analyses.
Results: The overall prevalence of MSI was 14%, highest in females (19%) and in proximal colon cancer (29%). Five-
year relapse-free survival (5-year RFS) was 67% and 55% (P = 0.030) in patients with MSI and MSS tumors,
respectively, with the hazard ratio (HR) equal to 1.60 (P = 0.045) in multivariate analysis. The improved outcome was
conﬁned to stage II patients who had 5-year RFS of 74% and 56% respectively (P = 0.010), HR = 2.02 (P = 0.040).
Examination of 12 or more lymph nodes was signiﬁcantly associated with proximal tumor location (P < 0.001).
Conclusions: MSI has an independent positive prognostic impact on stage II colorectal cancer patients after
complete resection.
Key words: adenocarcinoma, colorectal neoplasms, lymph nodes, microsatellite instability, prevalence, prognosis
introduction
Colorectal cancer is among the most common malignancies in
the western world [1] and is becoming more common in
developing countries as they approach a western lifestyle [2]. In
Norway, the age-adjusted incidence rate has doubled over the
last 50 years and is now among the highest in Europe [3].
Several clinical and pathological factors have prognostic
impact on colorectal cancer including tumor stage, residual
tumor (R-) status [4], tumor differentiation [5, 6], bowel
perforation and emergency surgery [7]. In colon cancer, the
number of examined lymph nodes has a prognostic impact
[8–11]. Risk stratiﬁcation according to these clinicopathological
factors is applied to select patients for (neo-) adjuvant
treatment. In Norway, stage III colon cancer patients with age
less than 76 years are offered adjuvant chemotherapy. Stage II
patients do not receive such therapy, except those with bowel
perforation or less than nine examined lymph nodes after a
thorough examination of the resected tissue. In rectal cancer,
preoperative radiochemotherapy is recommended if the
distance from the tumor or a metastatic lymph node to the
mesorectal fascia is ≤3 mm, evaluated by magnetic resonance
imaging.
However, current risk stratiﬁcation does not adequately
identify patients with good and poor prognosis. The 5-year
relative survival rate of stage III colon cancer patients was 57%
before adjuvant chemotherapy became standard treatment [3],
which implies that more than half of these patients are cured
by surgery alone and are over-treated when given adjuvant
therapy. Five-year relative survival in stage II colon cancer is
75% [12], indicating that 25% of the patients relapse and die of
cancer within 5 years after surgery. Possibly, adjuvant therapy
for high-risk stage II patients might improve these results.
Several biomarkers have been proposed to improve the
identiﬁcation of patients at risk of relapse, but none are
implemented in clinical practice [13].
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Approximately 15% of all colorectal cancers display
microsatellite instability (MSI), a molecular phenotype caused
by defect mismatch repair [14–17]. In Lynch syndrome
(former HNPCC), MSI is due to germline mutation in one of
the MMR genes, usually MLH1 or MSH2 [18–20]. In sporadic
colorectal cancer, MSI is mainly caused by epigenetic silencing
of MLH1 [21–23] and is characterized by poor differentiation,
tumor-inﬁltrating lymphocytes, location in the proximal colon
and association with female gender and age [14, 16, 17, 24–28].
We initially reported MSI as a marker of good prognosis in
1993 [14]. Subsequent reports have shown conﬂicting results;
however, a systematic review from 2005 concluded that
patients with MSI tumors have better prognosis than those
with MSS tumors [29] and a meta-analysis from 2010
conﬁrmed this ﬁnding [30]. It is yet to be decided whether this
is valid for all stages, and the results from different studies
differ at this point [24, 25, 28]. The aim of the present study
was to evaluate the prognostic impact of MSI adjusted for stage
and other clinical variables in a large, consecutive series from a
single hospital.
materials and methods
Oslo University Hospital, Aker has a deﬁned catchment area of 270 000
inhabitants. All patients with colorectal cancer admitted to the hospital in
the period 1993–2003 were registered and clinical data recorded in a
database. Registration has been controlled against the Norwegian Cancer
Registry.
Major resection was deﬁned as removal of the tumor-bearing bowel
segment with the lymphovascular pedicle and mesentery with regional
lymph nodes. Total mesorectal excision was carried out in all patients with
rectal cancer. Fifteen percent of the patients underwent emergency surgery,
due to obstruction or perforation of the bowel.
TNM-staging followed the UICC/AJCC system, version 5, for all
patients. Based on the radiological examinations, intraoperative ﬁndings
and macroscopic and microscopic examination, the resection was classiﬁed
as R0 (complete resection/no residual tumor), R1 (microscopic residual
cancer at the resection margin) or R2 (macroscopic or radiological
evidence of residual cancer, locally or distant). For colon cancer, the total
number of examined lymph nodes was registered.
The patients were split into three subgroups according to tumor
location: proximal colon including the cecum through the transverse colon;
distal colon including the left ﬂexure through the rectosigmoid ﬂexure;
rectum was deﬁned as the bowel up to 15 cm above the anal verge.
Colon cancer patients with age less than 76 years and all rectal cancer
patients who underwent curative surgery entered a 5-year follow-up
program (supplementary Table S1, available at Annals of Oncology online).
Patients who were not enrolled in systematic follow-up would be admitted
to our hospital if developing symptoms of relapse, implying that most
relapses would be identiﬁed and registered. Information about death was
retrieved from the Norwegian Tax Administration.
Figure 1. Flow chart for all patients with colorectal cancer admitted to Oslo University Hospital, Aker, in the period 1993–2003.
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Formalin-ﬁxed parafﬁn-embedded tumor tissue was retrieved for all
patients who had undergone major resection, and HE sections were re-
examined to conﬁrm the presence of cancer and mark the most
representative area. Four 25 μm sections were used for DNA extraction
with QIAamp DNA Mini kit from Qiagen (GmbH, Hilden, Germany). The
method was modiﬁed by adding an early step for removal of parafﬁn by
heating to 90°C for 10 min after buffer was added.
For determination of the MSI status, microsatellite analyses were carried
out for the ﬁve loci recommended by the National Cancer Institute [31].
PCR for the mononucleotides (BAT25 and BAT26) and the dinucleotides
(D2S123, D5S346 and D17S250) were run separately. Both the reactions
used 37 ng DNA templates in a 10 μl reaction volume consisting of a 1×
Multiplex PCR Master mix (buffer, 1.5 mM MgCl2, nucleotides and
enzyme, QUIAGEN GmbH, Hilden, Germany), ﬂuorescent primers and
water. The mononucleotide markers underwent 30 cycles and the
dinucleotide markers 35 cycles. Fragment analysis was accomplished on
3730 Genetic Analyzer (Applied Biosystems, Life Technologies, Carlsbad,
California). Four DNA samples extracted from blood of healthy donors
were included in each run as controls. The results were scored
independently by two observers. The MSI status for each locus was
determined after two independent runs with the same conclusion (MSI or
wild type). If there were contradictory results, the locus was scored as ‘not
determined’. Samples with two or more loci exhibiting abnormal allelic
ranges were scored as MSI high (MSI-H, from here on referred to as MSI).
If one locus was MSI and four loci were wild type, the sample was scored
as MSI low (MSI-L). Samples with wild type in all ﬁve loci were scored as
microsatellite stable (MSS). For further analyses, MSI-L and MSS were
included in the same group, and referred to as MSS, as were samples with
four wild-type loci and one ‘not determined’ locus.
The associations between MSI, number of examined lymph nodes and
different clinical variables were explored in contingency tables, and
Pearson’s chi-square test was applied. Logistic regression was used in
multivariate models to explore different variables’ impact on the MSI-status
and the number of examined lymph nodes.
The prognostic impact of MSI and clinical variables was analyzed with
5-year overall survival (5-year OS) as primary endpoint; death from any
cause was deﬁned as event and patients were censored 5 years after surgery.
The second endpoint was 5-year relapse-free survival (5-year RFS); deaths
from any cause and recurrence (locally and/or distant) were deﬁned as
events [32]. The patients were censored at loss to follow-up, deﬁned as the
last date for clinical or radiological examination or at 5 years after surgery.
Survival analyses were carried out using the Kaplan–Meier method, and
the survival distributions were compared with the log-rank test.
Multivariate analyses were carried out using Cox regression analyses, all






P OR 95% CI P
Total 805 112 (14)
Sex
Female 431 (54) 82 (19) <0.001 Ref
Male 374 (46) 30 (8) 0.41 0.24–0.70 0.001
Age
<60 years 146 (18) 18 (12) 0.241 Ref
60–70 years 164 (20) 16 (10) 0.42 0.18–1.00 0.051
70–80 years 300 (37) 46 (15) 0.61 0.30–1.24 0.174
>80 years 195 (24) 32 (16) 0.56 0.26–1.19 0.131
Tumor location
Proximal colon 327 (41) 96 (29) <0.001 Ref
Distal colon 274 (34) 12 (4) 0.14 0.07–0.27 <0.001
Rectum 204 (25) 4 (2) 0.05 0.02–0.13 <0.001
Stage
I 118 (15) 7 (6) <0.001 Ref
II 323 (40) 65 (20) 1.89 0.75–4.75 0.176
III 210 (26) 27 (13) 1.07 0.40–2.88 0.887
IV 154 (19) 13 (8) 0.83 0.17–4.03 0.818
Histopathologic grade
G1 + G2 685 (85) 65 (10) <0.001 Ref
G3 102 (13) 42 (41) 7.34 4.06–13.27 <0.001
Mucinous 9 (1) 4 (44) 4.93 1.12–21.71 0.035
Surgery
Elective 683 (85) 101 (15) 0.090 Ref
Acute 122 (15) 11 (9) 0.44 0.21–0.95 0.038
Residual tumor
R0 637 (79) 97 (15) 0.061 Ref
R1 17 (2) 3 (18) 1.21 0.24–6.10 0.813
R2 151 (19) 12 (8) 0.37 0.10–1.46 0.157
aContingency tables, chi-square test.
bLogistic regression, all included variables are displayed in the table.
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variables from univariate analyses were entered into the models. A P-value
of <0.05 was considered statistically signiﬁcant. All analyses were carried
out with SPSS 16.0 (IBM®SPSS®, IBM Corporation, Armonk, New York).
The study was carried out according to the Helsinki declaration and
approved by the Regional Ethics Committee for Medical Research (REK
approval 1.2005.1629) and the Norwegian Data Inspectorate.
results
The selection of patients included in the study is illustrated in
Figure 1 and the characteristics of the cohorts included in the
different analyses are displayed in the supplementary Table S2,
available at Annals of Oncology online. A total of 1274 patients
were admitted with colorectal cancer from 1993 to 2003 and
925 patients underwent major resection of a solitary tumor.
Tumor tissue was available from 888 and the MSI status was
successfully determined in 805 (91%) patients who were
included in the analyses of MSI prevalence.
MSI prevalence and clinical variables
MSI was demonstrated in 112 (14%) patients (Table 1). MSI
tumors were most frequent in the proximal colon and 86% of
the MSI tumors were located proximal to the splenic ﬂexure.
MSI was more common in females who had a greater
proportion of their tumors in the proximal colon (49% versus
31% in men, P < 0.001), but also had a higher frequency of
MSI in their proximal tumors (34% versus. 20% in men,
P = 0.005). The prevalence of MSI varied with tumor stage with
the lowest frequency in stage I (6%) and the highest in stage II
(20%). This was partly because stage I tumors were rare in the
proximal colon (n = 25, 8%), whereas stage II tumors were
frequent (n = 145, 44%). Including only proximal colon
cancers, the frequencies of MSI in stage I (n = 25), stage II
(n = 145), stage III (n = 82) and stage IV (n = 75) were 24%,
39%, 26% and 16%, respectively. MSI was most prevalent in
tumors with poor differentiation (G3) and in mucinous
tumors. In a multivariate analysis (Table 1), MSI was
associated with female gender, tumor location in proximal
colon, poor differentiation and elective surgery.
MSI and number of examined lymph nodes
In the analyses of number of lymph nodes, rectal cancer
patients were excluded, leaving 601 colon cancer patients.
Because of missing data for three patients, 598 patients were
included in the analyses. Twelve or more examined lymph
nodes were obtained in 31% of the patients and the






P OR 95% CI P
Total 598 186 (31)
MSI status
MSI 108 (18) 46 (43) 0.004 Ref
MSS 490 (82) 140 (29) 0.86 0.54–1.37 0.534
Sex
Female 337 (56) 117 (35) 0.030 Ref
Male 261 (44) 69 (27) 0.73 0.50–1.07 0.105
Age
<60 years 92 (15) 41 (45) 0.019 Ref
60–70 years 114 (19) 33 (29) 0.53 0.30–0.93 0.027
70–80 years 224 (38) 60 (27) 0.43 0.26–0.69 <0.001
>80 years 168 (28) 52 (31) 0.48 0.29–0.80 0.005
Tumor location
Proximal colon 324 (54) 128 (40) <0.001 Ref
Distal colon 274 (46) 58 (21) 0.45 0.30–0.67 <0.001
Stage
I 64 (11) 14 (22) 0.004 Ref
II 249 (42) 78 (31) 1.60 0.95–2.68 0.075
III 153 (26) 63 (41) 2.50 1.44–4.35 0.001
IV 132 (22) 31 (24) 1.04 0.56–1.92 0.906
Histopathologic grade
G1 + G2 498 (85) 155 (31) 0.903 Ref
G3 83 (14) 27 (33) 0.87 0.50–1.50 0.611
Mucinous 8 (1) 3 (38) 1.11 0.25–4.86 0.888
Surgery
Elective 482 (81) 153 (32) 0.284 Ref
Acute 116 (19) 33 (28) 0.90 0.56–1.46 0.674
aContingency tables, chi-square test.
bLogistic regression, all included variables are displayed in the table
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distribution according to clinical variables is presented in
Table 2. When including only tumors from the proximal colon
(n = 324), the numbers of patients with 12 or more examined
lymph nodes were 43 (45%) and 85 (37%) for MSI and MSS,
respectively (P = 0.203). If only including MSS tumors
(n = 490), the numbers with 12 or more lymph nodes were 85
(37%) and 55 (21%) for proximal and distal colon, respectively
(P < 0.001). In multivariate analyses, age, tumor location and
stage had a signiﬁcant impact on the proportion with 12 or
more examined lymph nodes, whereas the MSI status had no
signiﬁcant impact.
MSI and survival
The MSI status was successfully determined in 613 patients
with solitary tumors who survived for >3 months after an R0-
resection (Figure 1). These were included in the prognostic
analyses, and matched well with all patients who underwent
major resection with regard to age, gender and tumor location
(supplementary Table S2, available at Annals of Oncology
online). The group included 17 stage IV patients who
underwent R0-resection of synchronous, distant metastases
during or shortly after the primary operation.
Of the 613 patients included in the prognostic analyses, 157
(26%) experienced relapse and 224 (37%) died without known
relapse. The 5-year estimated relapse rates were 10%, 23% and
42% in stages I–III, respectively according to the Kaplan–Meier
method. For patients who survived without relapse, the median
follow-up time was 65 months.
The 5-year OS rates were 69% and 61% for patients with
MSI tumors and MSS tumors, respectively (P = 0.214), with the
hazard ratio (HR) equal to 1.47 (P = 0.112). However, MSI was
associated with signiﬁcantly improved 5-year RFS (Table 3).
Subgroup analyses demonstrated that the improved outcome
for MSI tumors only applied to stage II, whereas no difference
in the outcome was found in stage III (Figure 2). For stage I
and IV, the numbers of MSI tumors were too small to draw
any conclusions.
The prognostic impact of MSI status in stage II patients is
presented in Table 4, showing 5-year RFS of 74% and 56%
(P = 0.01) in MSI and MSS patients, respectively, with the HR
equal to 2.02 (P = 0.040).






P HR 95% CI P
Total 613 56.5
MSI status
MSI 92 (15) 67.1 0.030 Ref
MSS 521 (85) 54.7 1.60 1.01–2.52 0.045
Sex
Female 321 (52) 58.3 0.488 Ref
Male 292 (48) 54.6 1.10 0.85–1.43 0.451
Age
<60 111 (18) 74.8 <0.001 Ref
60–70 126 (21) 60.7 1.88 1.17–3.04 0.010
70–80 236 (39) 53.4 2.40 1.56–3.70 <0.001
>80 140 (23) 43.4 2.92 1.83–4.67 <0.001
Tumor location
Proximal colon 238 (39) 59.5 0.284 Ref
Distal colon 198 (32) 53.3 1.24 0.91–1.71 0.179
Rectum 177 (29) 56.1 1.51 1.07–2.13 0.019
Stage
I 117 (19) 75.0 <0.001 Ref
II 291 (48) 59.2 1.95 1.27–3.01 0.002
III 188 (31) 45.0 3.37 2.18–5.21 <0.001
IV 17 (3) 11.8 5.55 2.88–10.70 <0.001
Histopathologic grade
G1/G2 534 (87) 58.2 0.025 Ref
G3 66 (11) 45.1 1.84 1.24–2.73 0.003
Mucinous 7 (1) 57.1 1.31 0.42–4.15 0.642
Surgery
Elective 544 (89) 58.2 0.004 Ref
Acute 69 (11) 43.1 1.35 0.94–1.96 0.107
aKaplan–Meier estimate, log-rank test.
bCox Regression, all included variables are displayed in the table.
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discussion
The important ﬁnding in the present study was that stage II
patients with MSI tumors have better outcome than patients
with MSS tumors. This is in accordance with several other
publications [24, 28–30, 33–35]. This was demonstrated in a
large, consecutive and population-based series with minimal
risk of selection bias. The comprehensive set of clinical data
made it possible to adjust for several well-known prognostic
factors. Patients with synchronous tumors were excluded
because of the uncertainty regarding which tumor was most
relevant for prognosis. We chose robust endpoints according to
Punt et al. [32] and end points based on the cause of death
were not considered due to the risk of bias due to erroneous
cause of death. Analyses were restricted to 5-year survival, as
most deaths after this time will not be cancer related. Patients
were censored at the time of the last examination with regard
to recurrence, and bias due to loss of follow-up was minimized.
This report follows the recommendations for tumor marker
prognostic studies [36]. Based on these conditions, the
conclusion with regard to the prognostic impact of MSI is
reliable.
The positive prognostic impact of MSI was conﬁned to stage
II patients. In contrast, Samowitz et al. found signiﬁcant
impact only in stage III patients in a study of 1000 colon
cancer patients from California and Utah, all less than 79 years
of age, and with different ethnic background [28]. Benatti et al.
presented a series of 1263 colorectal cancer patients and found
a positive prognostic impact of MSI in stage II and III [24].
Patients with clinical suspicion of hereditary colorectal cancer
syndromes were also included in this study and the mean age
was only 65 years. The prevalence of MSI was unusually high
(20%). The current series has the advantage of not being
biased by any selection among the enrolled patients.
From 1997, patients up to 75 years with stage III colon
cancer receive 5FU-based adjuvant treatment. A systematic
review with meta-analysis from 2009 reported that MSI tumors
do not respond to this treatment [37] and this could
Figure 2. Five year relapse-free survival (RFS), stage II and III, n = 479.
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camouﬂage an otherwise better prognosis for MSI tumors in
stage III in our series. The patients who have received adjuvant
treatment comprise 56 patients of whom 11 had MSI tumors.
Excluding these from the analyses did not result in increased
prognostic impact of MSI in stage III (data not shown).
The clinical applicability of MSI as a prognostic marker
remains to be decided. Clearly, stage II tumors in the proximal
colon make up the interesting subgroup because of the high
prevalence of MSI (38%). Stage II patients do not routinely
receive adjuvant therapy according to Norwegian guidelines.
This seems reasonable for patients with an expected 5-year
relative survival of 75% [12]. However, the MSS subgroup of
patients had signiﬁcantly worse prognosis, and these patients
might beneﬁt from adjuvant therapy. To demonstrate such a
beneﬁt, a randomized trial is necessary. Additional molecular
markers may reﬁne the poor and good MSI-based prognostic
groups such as the recent ColoGuideEx, a 13 gene expression
signature speciﬁc to stage II patients published by our group
[38].
The prevalence of MSI in the current series was 14%. This is
in accordance with comparable series [33, 39–42]. The
previous documented association of MSI phenotype with right-
sided colorectal cancer was conﬁrmed. MSI was also more
common in women than in men, partly due to the fact that
women had a higher proportion of their tumors in the
proximal colon (49%) compared with men (31%), which is in
agreement with a study from New Zealand [43], but also
because women had a higher frequency of MSI in their
proximal tumors than men.
We found no signiﬁcant association between MSI status and
age. Other studies report the highest frequencies of MSI
tumors in the oldest patients [28, 33, 44].
The proportion of MSI tumors was highest in stage II. This
observation is in compliance with several other studies [24–26,
28, 40, 42]. The low number of MSI tumors in stage I in the
present series can partly be explained by few stage I tumors in
the proximal colon and numerous stage I tumors in the
rectum. This ﬁnding might be connected to the absence of
systematic screening for colorectal cancer in Norway which
implies that most patients have developed symptoms at the
time of diagnosis. Tumors in the proximal colon typically
cause more subtle symptoms than tumors in the distal colon
and rectum and may have reached a more advanced stage by
the time of detection. The high frequency of MSI in stage II
tumors might also reﬂect a less aggressive phenotype with
lower tendency to metastasize [25].
The number of examined lymph nodes was low in this
series, but probably representative for consecutive series from a






P HR 95% CI P
Total 291 59.2
MSI status
MSI 58 (20) 73.8 0.010 Ref
MSS 233 (80) 55.7 2.02 1.03–3.95 0.040
Sex
Female 156 (54) 60.5 0.677 Ref
Male 135 (46) 57.7 1.06 0.72–1.56 0.782
Age
<60 46 (16) 79.9 <0.004 Ref
60–70 53 (18) 65.4 1.91 0.84–4.32 0.122
70–80 118 (41) 53.9 2.91 1.42–5.97 0.004
>80 74 (25) 50.3 3.15 1.48–6.73 0.003
Tumor location
Proximal colon 133 (46) 64.9 0.010 Ref
Distal colon 91 (31) 58.1 1.18 0.73–1.91 0.505
Rectum 67 (23) 49.5 2.23 1.33–3.74 0.002
pT stage
3 272 (93) 59.6 0.458 Ref
4 19 (7) 52.6 1.72 0.84–3.50 0.138
Histopathologic grade
G1/G2 250 (86) 59.3 0.756 Ref
G3 32 (11) 62.8 1.61 0.79–3.30 0.190
Mucinous 6 (2) 66.7 1.41 0.32–6.17 0.647
Surgery
Elective 252 (87) 61.2 0.018 Ref
Acute 39 (13) 45.7 1.81 1.07–3.08 0.028
aKaplan–Meier estimate, log-rank test.
bCox regression, all included variables are displayed in the table.
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routine setting in this period. However, the low number should
not introduce any bias in the calculations since this inﬂuences
MSI/MSS and different tumor locations equally. Other authors
have reported a higher number of examined lymph nodes in
MSI patients [45–47], and suggested that MSI tumors induce
larger lymph nodes which are more easily identiﬁed and
retrieved by the pathologist. However, when adjusting for
tumor location, the effect of MSI disappeared [47]. This is in
line with our ﬁnding. A probable explanation is that different
tumor locations result in different anatomical resections with
unequal numbers of lymph nodes due to the anatomical
distribution of mesocolic lymph nodes.
There is a correlation between the number of examined
lymph nodes and correct staging [9], and this might explain
why stage III patients have the highest number of examined
lymph nodes. The correlation between the number of
examined lymph nodes and age has also been described by
others [10]. In the present series, a higher proportion of
patients <60 years in the more recent years, corresponding to a
period with increasing number of examined lymph nodes [48],
might explain this.
In conclusion, the present study demonstrates that MSI is a
positive prognostic factor in patients with stage II colon cancer,
but not in stage III. MSS could be a clinical useful biomarker
for the identiﬁcation of patients with stage II right-sided colon
cancer at increased risk of relapse.
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VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms
as predictors of survival in pancreatic carcinoma
F. G. Uzunoglu1,†, J. Kolbe1,†, H. Wikman2, C. Güngör1, B. A. Bohn1, M. F. Nentwich1, M. Reeh1,
A. M. König1, M. Bockhorn1, A. Kutup1, O. Mann1, J. R. Izbicki1 & Y. K. Vashist1*
Departments of 1General, Visceral and Thoracic Surgery; 2Tumour Biology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
Received 16 June 2012; revised 5 November 2012; accepted 7 November 2012
Background: Hypoxic environment of pancreatic cancer (PC) implicates high vascular in-growth, which may be
inﬂuenced by angiogenesis-related germline polymorphisms. Our purpose was to evaluate polymorphisms of vascular
endothelial growth factor receptor 2 (VEGFR-2), CXC chemokine receptor 2 (CXCR-2), proteinase-activated receptor 1
(PAR-1) and endostatin (ES) as prognostic markers for disease-free (DFS) and overall survival (OS) in PC.
Patients and methods: Genotyping of 173 patients, surgically treated for PC between 2004 and 2011, was carried
out by TaqMan® genotyping assays or polymerase chain reaction. Chi-square test, Kaplan–Meier estimator and Cox
regression hazard model were used to assess the prognostic value of selected polymorphisms.
Results: VEGFR-2 −906 T/T and PAR-1 −506 Del/Del genotypes predicted longer DFS (P = 0.003, P = 0.014) and
OS (VEGFR-2 −906, P = 0.011). CXCR-2 +1208 T/T genotype was a negative predictor for DFS (P < 0.0001).
Combined analysis for DFS and OS indicated that patients with the fewest number of favorable genotypes
simultaneously present (VEGFR-2 −906 T/T, CXCR-2 +1208 C/T or C/C and PAR-1 −506 Del/Del) were at the highest
risk for recurrence or death (P < 0.0001).
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Table 1. Five year follow-up program for colon cancer patients ≤ 75 years and all rectal cancer 
patients after complete resection. 
 Serum Radiologic examination Endoscopic procedure 
Months after surgery CEA Liver1 Lungs2 Coloscopy Proctoscopy3 
1 x     
6 x x x  x 
12 x x x  x 
18 x x x  x 
24 x x x  x 
30 x x x  x 
36 x x x  x 
42 x     
48 x x x  x 
54 x     
60 x x x x x 
1Ultrasonography of liver (computed tomography after 2006)  2Chest x-ray (computed tomography after 2006)  3Only rectal cancer 
after low anterior resection 
 
 
Table 2. Characteristics of the cohorts included in the different analyses. 
 All patients  Analyses of prevalence of MSI 
Prognostic analyses 
 
Variables N (%) N (%) N (%) 
Age    
 Median (range) 74,3 (18.8 – 96.6) 73.2 (29.9 – 94.5) 73,0 (29.9 – 94.5) 
 < 60 y 202 (16) 146 (18) 111 (18) 
 60 – 70 243 (19) 164 (20) 126 (21) 
 70 – 80 466 (37) 301 (37) 236 (38) 
 > 80 363 (28) 194 (24) 140 (23) 
Sex    
 Female 674 (53) 431 (54) 321 (52) 
 Male 600 (47) 374 (46) 292 (48) 
Tumor location    
 Proximal colon 451 (35) 327 (41) 238 (39) 
 Distal colon 374 (29) 274 (34) 198 (32) 
 Rectum 389 (31) 204 (25) 177 (29) 
 Synchronous 30 (2) 0 0 
 Unknown 30 (2) 0 0 
Stage    
 I 155 (12) 118 (15) 117 (19) 
 II 382 (30) 323 (40) 291 (48) 
 III 251 (20) 210 (26) 188 (31) 
 IV 312 (25) 154 (19) 17 (3) 
 Unknown 174 (14) 0 0 
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